small molecule

VEOZAH

FEZOLINETANT

Loss of exclusivityMarch 2034latest FDA-listed patent expiry

CompanyAstellas Pharma Us →See this company's full patent-cliff portfolio

Drug detail

Brand name	VEOZAH
Active ingredient	FEZOLINETANT
Strength	45MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
10836768	March 2034	use U-3622
9987274	March 2034	use U-3622
9422299	March 2034	substance, product
8871761	April 2031	substance

Regulatory exclusivity

Code	Expires
NCE	May 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Astellas Pharma Us